Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to...
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a...
Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits...
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.